Skip to main content

Patent litigation in Singapore.

Patent litigation in Singapore. The process involves several steps:

1. Filing a Writ of Summons:

The plaintiff initiates the litigation by filing a Writ of Summons, outlining their claims and relief sought. This officially starts the lawsuit.

2.Serving Court Documents: 

The plaintiff serves the court documents to the defendant, who responds by filing a Memorandum of Appearance to indicate their participation in the case.

3.Pleadings and Statements of Case: 

Both parties exchange their statements of case, including the Statement of Claim by the plaintiff and the Statement of Defence by the defendant. Further statements and counterclaims might also be filed.

4.Case Management Conference (CMC): 

The court schedules a CMC to manage the case's progress, including issues like discovery, evidence, and trial dates.

5.Discovery: 

Each party gathers and discloses relevant documents and evidence that will be used during the trial. This can include expert reports, technical documents, and communication records.

6.Interlocutory Applications: 

If necessary, either party can make applications for interim relief or specific orders from the court to address various aspects of the case.

7.Trial: 

The trial phase involves presenting arguments, evidence, and witnesses before the court. Expert witnesses might be called upon to provide their opinions on technical matters.

8.Judgment: 

After hearing both sides, the judge delivers a judgment, which could involve findings on patent validity, infringement, damages, and other related matters.

9.Appeal: 

If either party is dissatisfied with the judgment, they can appeal to a higher court, such as the Court of Appeal, based on specific legal grounds.

10.Enforcement: 

If the judgment favors the plaintiff, they can take steps to enforce their rights and remedies as determined by the court.

Singapore's Intellectual Property (IP) Court, part of the Singapore High Court, specializes in handling IP-related cases, including patent litigation. The court has established procedures and specialized judges to ensure efficient handling of these complex cases.

Keep in mind that patent litigation can be intricate and time-consuming. Legal representation by experienced IP lawyers is often recommended to navigate the complexities of the process effectively.

Comments

Popular posts from this blog

Pharma Companies HR contact information

Dear viewers of my blog, I am happy to share the HR contact details of Pharmaceutical companies. Contact Details Of Pharma HRs : Zaydus cadila-Goa gajendravernekar@zayduscadila.com 09623458512/08326615143 Teva-Goa Maryann.Braganza@teva.co.in sanjay.pandit@teva.co.in 0832 6685538 Glenmark-Goa Vittal hebbalkar hr executivr - 9923476869 anupbannatti@glenmark-generics.com 09604151586 Watson-Goa Jyosna.bagule@watsonpharm.co.in runa.divkar@watsonpharm.co.in goa@watsonpharm.co.in 0832 6690666/777 Unichem Labs-Goa abhiram.panshikar@unichemlabs.com R&D  suraj.jadhav@unichemlabs.com vikas.parkar@unichemlabs.com Indico-Goa goahplc@Indoco.com varun.keny@indoco.com anand.ingole@Indoco.com 0832 6624109 Encube-Goa hr@encubeethicals.com nidhi.b@encubeethicals.com 8322392223 Torrent pharma-Ahmdabad mayurdesai@torrentpharma.com 9879603921/22/23/24 Emcure-pune RPKulkarni@emcure.co.in           Kishor.Mule@emcure.co.in Rahul.Morgaonkar@emcure.co.in recruitment@em

Novo Nordisk settles with 2 Florida venders of compounded (Semaglutide)Ozempic:

Novo Nordisk settles with 2 Florida venders of compounded Ozempic: Novo Nordisk has arrived at private settlements with two Florida merchants of intensified forms of the uber blockbuster semaglutide therapies Ozempic and Wegovy, the organization said on Friday. In June of last year, Novo recorded brand name encroachment claims against five dealers of knockoff renditions of the GLP-1 medications, which have seen soaring interest to battle weight reduction. Ekzotica Corp's. Restorative Laser Experts Drug Spa in Miami and Effinger Wellbeing's Nuvida Rx Weight reduction in Tallahassee are the initial two organizations to have settled their cases. As indicated by long-lasting directive orders, the dealers will quit utilizing Novo reserve and have consented to reveal for a considerable length of time that intensified variants of the medications have not gone through the security and viability norms expected by the FDA for supported drugs. "The litigants' unlawful showcasing

Hypertension-An Overview

INTRODUCTION: Systemic arterial hypertension is one of the strongest known modifiable risk factors for ischaemic heart disease, stroke, renal failure and heart failure. It remains poorly treated. As an asymptomatic disorder, people are understandably reluctant to accept adverse drug effects in addition to the inconvenience of long-term treatment. In this regard, modern drugs represent an enormous improvement. PATHOPHYSIOLOGY AND SITES OF DRUG ACTION Hypertension is occasionally secondary to some distinct disease. However, most patients with persistent arterial hypertension have essential hypertension. Arterial blood pressure is determined by cardiac output, peripheral vascular resistance and large artery compliance. Peripheral vascular resistance is determined by the diameter of resistance vessels (small muscular arteries and arterioles) in the various tissues. One or more of a ‘mosaic’ of interconnected predisposing factors (including positive family history, obesity and phys